Interestingly, this analysis showed that FGF pathway amplification–negative patients were unlikely to respond to dovitinib, as 16 out of 28 patients (57.1%) without FGF-pathway amplification presented either a new lesion or tumor size increase as best response, compared with only 1 out of 10 (10.0%) FGF-pathway–amplified patients. Similar results were obtained when amplification of FGFR1 or FGFR2 was used to define FGF-pathway amplification as only 1 patient presented with FGF3 amplification but not FGFR1 or FGFR2 amplification.